Related Experiment Videos
PR-39, a proline/arginine-rich antimicrobial peptide, prevents postischemic microvascular dysfunction.
R J Korthuis1, D C Gute, F Blecha
1Department of Molecular and Cellular Physiology, Louisiana State University Medical Center, School of Medicine in Shreveport, Shreveport, Louisiana 71130, USA. rkorth@lsumc.edu
The American Journal of Physiology
|September 14, 1999
Summary
PR-39, a neutrophil antibacterial peptide, prevents intestinal ischemia-reperfusion injury by inhibiting leukocyte adhesion and oxidant production. This peptide may offer therapeutic benefits for postischemic inflammation.
Area of Science:
- Biomedical Science
- Physiology
- Immunology
Background:
- Intestinal ischemia-reperfusion (I/R) injury increases oxidant production, disrupting the microvascular barrier.
- Activated neutrophils contribute significantly to tissue damage during reperfusion.
Purpose of the Study:
- To investigate if PR-39, a neutrophil NADPH oxidase inhibitor, prevents postischemic oxidant production and microvascular leakage.
- To evaluate PR-39's effect on leukocyte adhesion and emigration during I/R.
Main Methods:
- In vivo studies monitored oxidant production, protein leakage, and leukocyte activity in rat mesenteric venules subjected to I/R with or without PR-39.
- In vitro experiments assessed PR-39's impact on neutrophil chemotaxis and endothelial cell adhesion molecule expression.
Main Results:
- PR-39 administration abolished I/R-induced leukocyte adhesion and emigration.
- PR-39 inhibited oxidant production and venular protein leakage during reperfusion.
- In vitro, PR-39 reduced neutrophil chemotaxis and endothelial cell adhesion molecule-1 expression.
Conclusions:
- PR-39 effectively prevents postischemic leukocyte adhesion and emigration.
- PR-39's anti-inflammatory effects are likely mediated by its antiadhesive properties.
- PR-39 shows therapeutic potential for mitigating neutrophil-driven inflammation in I/R injury.